NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.

Also called NCT01495364

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 195 participants (enrolled count) (from the registry)
Sponsor
Lisata Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT01495364
Other papers using this trial's data
  • PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI Circulation research, 2017-01-20 DOI, PubMed 27821724, PMC5903285 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01495364. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
Acronym
PreSERVE-AMI
Condition
ST Segment Elevation Myocardial Infarction
Intervention (Biological)
NBS10
Intervention (Other)
placebo
Lead sponsor
Lisata Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01495364
Content hash
81e714eca4b3514370d9ccba6738aee97c5515dfa27c054607bb1e640dfb7f37